Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem c...

BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these i...

Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Qu...

Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron...

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq ...

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demons...

Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage...

Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with...

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AG...